(6-Bromo-4-{4-[(dimethylamino)methyl]piperidin-1-yl}quinolin-3-yl)(cyclopropyl)methanone → [6-(3-Chloro-4-hydroxy-5-methoxyphenyl)-4-{4-[(dimethylamino)methyl]piperidin-1-yl}quinolin-3-yl](cyclopropyl)methanone
Reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2[N:17]1[CH2:22][CH2:21][CH:20]([CH2:23][N:24]([CH3:26])[CH3:25])[CH2:19][CH2:18]1.[Cl:27][C:28]1[CH:33]=[C:32](B2CC(C)(C)C(C)(C)C2)[CH:31]=[C:30]([O:43][CH3:44])[C:29]=1[OH:45]>>[Cl:27][C:28]1[CH:33]=[C:32]([C:2]2[CH:3]=[C:4]3[C:9](=[CH:10][CH:11]=2)[N:8]=[CH:7][C:6]([C:12]([CH:14]2[CH2:16][CH2:15]2)=[O:13])=[C:5]3[N:17]2[CH2:22][CH2:21][CH:20]([CH2:23][N:24]([CH3:26])[CH3:25])[CH2:19][CH2:18]2)[CH:31]=[C:30]([O:43][CH3:44])[C:29]=1[OH:45]Participants
3
Reactant 2
Product 1
Procedure
Following general procedure D, (6-bromo-4-{4-[(dimethylamino)methyl]piperidin-1-yl}quinolin-3-yl)(cyclopropyl)methanone (35 mg, 0.084 mmol) was reacted with 2-chloro-6-methoxy-4-(3,3,4,4-tetramethylborolan-1-yl)phenol (42 mg, 0.150 mmol) to afford the desired product (29.1 mg, 70%) as an off-white solid: 1H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H), 8.30 (s, 1H), 8.07-7.99 (m, 2H), 7.31 (d, J=2.0 Hz, 1H), 7.25 (d, J=1.9 Hz, 1H), 4.00 (s, 3H), 3.54 (d, J=12.4 Hz, 2H), 3.22 (t, J=12.2 Hz, 2H), 2.59-2.50 (m, 1H), 2.43 (d, J=6.2 Hz, 2H), 2.35 (s, 6H), 2.01-1.83 (m, 3H), 1.67-1.53 (m, 2H), 1.35-1.27 (m, 2H), 1.27-1.19 (m, 2H); ESI MS m/z 494 [C28H32ClN3O3+H]+; HPLC 98.9% (AUC), tR=10.51 min.
Sources & evidence
- ORD record
- ord-0180e6ca5dc4495aa574dcad0d9023e9
- Source dataset
- uspto-grants-2015_09
- Patent number
- US09120749B2
Reaction notes
Loading…